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Abstract
The prevalence of trisomy 21 has been reported to differ by race–ethnicity, however, the results 
are inconsistent and the cause of the differences is unknown. Using data from 1996 to 2005 from 
the Metropolitan Atlanta Congenital Defects Program (MACDP), we analyzed the use of prenatal 
cytogenetic testing and the subsequent use of elective termination among pregnancies affected 
with any MACDP-eligible birth defect and trisomy 21, by maternal race–ethnicity. We then 
examined whether these factors could explain the observed differences in the prevalence of 
trisomy 21 among race–ethnicity groups. Among all pregnancies with birth defects, prenatal 
cytogenetic testing as well as elective terminations after an abnormal prenatal cytogenetic test 
result were observed less frequently among Hispanic women than among non-Hispanic white 
women (odds ratio [OR] 0.66, 95% confidence interval [CI] 0.56–0.78, respectively). In 
pregnancies affected by trisomy 21, both the Hispanic and the non-Hispanic black populations had 
more live births (89.5% and 77.8%, respectively) and fewer elective terminations (5.7% and 
15.2%, respectively) compared to the non-Hispanic white population (63.0% live births, 32.3% 
elective terminations). After adjusting for elective terminations, non-Hispanic white mothers had a 
higher live birth prevalence of trisomy 21 compared to non-Hispanic black (OR 0.64, 95% CI 
0.54–0.76) or Hispanic mothers (OR 0.69, 95% CI 0.55–0.86). Overall, our data suggest that 
factors associated with decisions made about the use of prenatal testing, and about pregnancy 
management after testing, might play a large role in the race–ethnicity differences observed in the 
live birth prevalence of trisomy 21.
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INTRODUCTION
There has been debate in the literature regarding whether trisomy 21 (Down syndrome) 
occurs more often among Hispanic women, with some studies finding as much as a 20% 
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higher prevalence estimate compared to non-Hispanic white women [Centers for Disease 
Control and Prevention, 1994; Hook et al., 1999; Canfield et al., 2006; Shin et al., 2009] 
while others find no significant difference in prevalence among race–ethnicity groups 
[Bishop et al., 1997]. To diagnose a pregnancy affected by trisomy 21 or other chromosomal 
abnormality, a prenatal cytogenetic test is typically performed following the removal of 
tissue through chorionic villus sampling (CVS) or amniocentesis. Factors influencing the 
use of prenatal testing are thought to include opinions towards the reliability and usefulness 
of test results, attitudes regarding elective termination, willingness to proceed with a 
pregnancy in which a birth defect was recognized, and access to care [Press and Browner, 
1998; Li et al., 2008]. Both CVS and amniocentesis have associated risks of pregnancy 
complications and loss [Caughey et al., 2006], making some women reluctant to utilize these 
procedures. Use of prenatal cytogenetic testing allows for options in the event of abnormal 
findings such as arranging for specialized birth facilities and neonatal care, pregnancy 
termination, acquiring medical knowledge about the condition diagnosed, and finding 
support communities.
Differences in the utilization of prenatal diagnosis by race–ethnicity have been observed, 
with reports of less frequent use of amniocentesis among non-Hispanic blacks and Hispanics 
compared with non-Hispanic whites [Brett et al., 1994; Baker et al., 2004]. In addition, 
opinions about and use of elective pregnancy termination have been shown to differ by 
race–ethnicity [Harris and Mills, 1985; Jones et al., 2010; Pazol et al., 2011]. Prenatal 
diagnostic testing and elective termination affect the live birth prevalence of trisomy 21 
[Mikkelsen, 1992; Cornel et al., 1993; Krivchenia et al., 1993; Bishop et al., 1997; Forrester 
and Merz, 1999], but the specific relationship between race–ethnicity differences in the 
uptake of prenatal cytogenetic testing and elective termination after prenatal diagnosis, and 
live birth prevalence has not been carefully examined.
Data from the Metropolitan Atlanta Congenital Defects Program (MACDP) have been used 
to assess the frequency of elective termination on the prevalence of trisomy 21 by maternal 
age [Cragan and Gilboa, 2009] and by maternal race [Siffel et al., 2004]. However, these 
analyses did not evaluate the role of differences in utilization of prenatal cytogenetic 
diagnosis or of elective pregnancy termination after prenatal diagnosis. We used MACDP 
data from 1996 to 2005 to examine the utilization of prenatal cytogenetic testing among 
pregnancies affected with a birth defect, the utilization of elective termination after prenatal 
diagnosis of a defect, and the prevalence of trisomy 21 by maternal race–ethnicity. We 
hypothesized that differences in the utilization of prenatal cytogenetic testing and elective 
termination influence the observed race–ethnicity differences in the prevalence of trisomy 
21.
MATERIALS AND METHODS
MACDP is a population-based birth defects surveillance system covering residents of the 
five central metropolitan Atlanta counties at the time of delivery. MACDP methods have 
been published previously [Correa et al., 2007]. Briefly, for inclusion in MACDP, the fetus, 
infant, or child must have been diagnosed with a major structural defect or chromosomal 
abnormality either prenatally or before the child’s sixth birthday. Since 1968, trained 
Jackson et al. Page 2













abstractors have actively ascertained birth defects data for live and stillborn infants 
delivered, and pregnancies electively terminated, at ≥20 weeks gestation from birth and 
pediatric hospitals. The Georgia Department of Public Health, Office of Vital Records, and 
selected clinical laboratories have directly submitted data. Beginning in 1994, to better 
ascertain pregnancies diagnosed prenatally with birth defects, record collection expanded to 
include affected pregnancies at any gestational age identified through maternal–fetal 
medicine departments and perinatal offices, and those electively terminated after prenatal 
diagnosis. Each abstracted defect is assigned a six-digit code using a coding system 
modified by the Centers for Disease Control and Prevention that is based on the British 
Paediatric Association coding system and the International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) [Rasmussen and Moore, 2001; Division of 
Birth Defects and Developmental Disabilities and National Center on Birth Defects and 
Developmental Disabilities, 2007].
For these analyses, we categorized maternal race–ethnicity as non-Hispanic white, non-
Hispanic black, or Hispanic as designated in the delivery or medical record. We categorized 
pregnancy outcomes as live birth, fetal death ≥20 weeks gestation, elective termination after 
prenatal diagnosis of a birth defect at any gestational age, or unknown outcome. The latter 
were pregnancies diagnosed prenatally with a birth defect for which a delivery record was 
not found at the MACDP ascertainment sources (birth hospitals, perinatal offices, and 
maternal–fetal medicine departments). We calculated prevalence estimates as the number of 
deliveries with cytogenetically confirmed trisomy 21 (whole chromosome and 
translocations) divided by the total number of live births in the MACDP region. Consistent 
with other birth defects surveillance systems, population denominators for prevalence 
estimates were based on live births obtained from birth certificates and did not include fetal 
deaths or elective terminations [National Birth Defect Prevention Network, 2004].
First, we estimated the unadjusted prevalence of trisomy 21 among all pregnancy outcomes 
(live births, fetal deaths, elective terminations, and unknown outcome) for the entire 
MACDP population and for each of the three individual race–ethnicity subgroups, and 
compared each with that for non-Hispanic white women using chi-square with 95% 
confidence intervals. We also estimated the total live birth prevalence and the prevalence 
adjusted for elective terminations for births affected by trisomy 21. Approximately 74% of 
pregnancies electively terminated after prenatal diagnosis of trisomy 21 would be expected 
to result in a livebirth if elective termination had not occurred [Hook et al., 1989; Bishop et 
al., 1997] and thus would have contributed to the live birth rate. To estimate the live birth 
prevalence adjusted for elective terminations, we multiplied the number of elective 
terminations for trisomy 21 by 0.74 and added this number to the number of live births with 
trisomy 21 and the total number of live births [adjusted live births = live births + (elective 
terminations × 0.74)] [Krivchenia et al., 1993; Bishop et al., 1997].
Next, we used multivariate logistic regression to estimate odds ratios for whether a prenatal 
cytogenetic test was performed (tested vs. not tested), and whether an elective termination 
was performed (performed vs. not performed) after prenatal cytogenetic testing regardless of 
the result and after a prenatal cytogenetic test with an abnormal result, for all pregnancies 
with birth defects in MACDP comparing each race–ethnicity group with non-Hispanic white 
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women. We adjusted all models for maternal age as a continuous variable and birth year of 
the index pregnancy. Finally, we calculated the number of each birth outcome among all 
pregnancies with defects and among pregnancies with trisomy 21, the percent of the total, 
and 95% confidence interval for the percentage by race–ethnicity group. Statistical analyses 
were done using SPSS 18 [SPSS: An IBM Company, 2009] and SAS software version 9.2 
[SAS Institute Inc., 2008].
RESULTS
Prevalence of Trisomy 21
We estimated the prevalence of trisomy 21 among all pregnancy outcomes for the three 
race–ethnicity groups during the years 1996–2005 (Table I). Compared with non-Hispanic 
whites, a significantly lower prevalence of trisomy 21 was observed among non-Hispanic 
black and Hispanic pregnancies in the combined maternal age category (prevalence ratio 
[PR] = 0.62, 95% confidence interval [CI] 0.53–0.73 and PR = 0.64, 95% CI 0.52–0.8, 
respectively). Non-Hispanic black mothers aged <35 years had a significantly lower 
prevalence of trisomy 21 pregnancies compared with non-Hispanic white mothers aged <35 
years (PR = 0.74, 95% CI 0.58–0.95). However, the prevalence of trisomy 21 among 
Hispanic mothers aged <35 years was similar to that among non-Hispanic white mothers 
aged <35 years; the prevalence of trisomy 21 among mothers 35 years and older did not vary 
significantly by maternal race–ethnicity.
Unadjusted and Adjusted Live Birth Prevalence of Trisomy 21
The live birth prevalence of trisomy 21, and the live birth prevalence adjusted for electively 
terminated trisomy 21 pregnancies, were calculated for each of the three race–ethnicity 
subgroups (Table I). The live birth prevalence of trisomy 21 was significantly lower among 
non-Hispanic black mothers of all ages compared with non-Hispanic white mothers of all 
ages (PR = 0.77, 95% CI 0.64–0.93; Table I). When adjusted for elective termination, the 
live birth prevalence of trisomy 21 among both non-Hispanic black and among Hispanic 
mothers of all ages were statistically significantly lower compared with non-Hispanic white 
mothers (PR = 0.64, 95% CI 0.54–0.76, and PR = 0.69, 95% CI 0.55–0.86, respectively). 
Non-Hispanic black mothers aged <35 years also had a significantly lower live birth 
prevalence when adjusted for elective termination compared with non-Hispanic white 
mothers aged <35 (PR = 0.76, 95% CI 0.59–0.98). However, the adjusted live birth 
prevalence of trisomy 21 among Hispanic mothers aged <35 years was similar to that among 
non-Hispanic white mothers aged <35; the adjusted live birth prevalence of trisomy 21 
among mothers 35 years and older did not vary significantly by maternal race–ethnicity.
Prenatal Cytogenetic Testing and Elective Termination in Race–Ethnicity Groups 
Comprising All MACDP-Eligible Birth Defects
Prenatal cytogenetic testing was reported significantly less frequently among Hispanic 
women (Table II) compared with non-Hispanic white women (odds ratio [OR] 0.66, 95% CI 
0.56–0.78) using a multivariate logistic regression model to adjust for birth year and 
maternal age. In contrast, non-Hispanic black women underwent a similar frequency of 
prenatal cytogenetic testing (OR 0.95, 95% CI 0.87–1.00). However, compared with non-
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Hispanic white women, both non-Hispanic black and Hispanic women were significantly 
less likely to undergo elective termination after an abnormal prenatal cytogenetic test result 
(OR 0.50, 95% CI 0.36–0.70 and OR 0.49, 95% CI 0.27–0.88, respectively).
Pregnancy Outcomes
The outcomes of all pregnancies with defects and of those pregnancies affected by trisomy 
21 were analyzed for the years 1996–2005 by maternal race–ethnicity (Table III). Among all 
pregnancies with defects ascertained by MACDP, live births occurred most frequently 
among Hispanics and fetal deaths occurred most frequently among non-Hispanic blacks; 
elective termination occurred most frequently among non-Hispanic white pregnancies. 
Among pregnancies affected by trisomy 21, live births occurred most frequently among 
Hispanic and non-Hispanic black pregnancies, while elective terminations occurred most 
frequently among non- Hispanic white pregnancies. Fetal deaths were similar between race-
ethnicities but occurred most frequently among non-Hispanic black pregnancies.
DISCUSSION
Utilization of Prenatal Cytogenetic Testing and Elective Pregnancy Termination
We found that maternal race–ethnicity was associated with both the utilization of prenatal 
cytogenetic testing and termination of a pregnancy after diagnosis of a birth defect. 
Compared with non-Hispanic white mothers, Hispanic mothers underwent prenatal 
cytogenetic testing significantly less often. This finding is in keeping with the literature 
which also has shown lower use of amniocentesis among Hispanic women [Baker et al., 
2004]. It has been hypothesized that race–ethnicity differences in the utilization of prenatal 
diagnosis are due in part to differences in attitudes towards elective terminations [Press and 
Browner, 1998; Li et al., 2008]. This is supported by our finding that non-Hispanic black 
and Hispanic women were significantly less likely to undergo elective termination after an 
abnormal result from a prenatal cytogenetic test.
Total and Live Birth Prevalence of Trisomy 21
In comparing the overall prevalence of trisomy 21 among race–ethnicity groups, both the 
non-Hispanic black and Hispanic populations had a statistically significantly lower 
prevalence than the non-Hispanic white population; however, when only the live birth 
prevalence was examined, a statistically significant difference remained only for the non-
Hispanic black population. The proportion of pregnancies with trisomy 21 that resulted in 
fetal death was similar among race–ethnicity groups (3.9% non-Hispanic white, 4.5% non-
Hispanic black, and 3.8% Hispanic), suggesting that the differences in the overall prevalence 
of trisomy 21 largely reflect variations in the proportion of affected pregnancies that resulted 
in elective termination (32.3% non-Hispanic white, 15.2% non-Hispanic black, and 5.7% 
Hispanic). Indeed, when the live birth prevalence was adjusted for the estimated 74% of 
elective terminations that would have otherwise resulted in a live birth, both the non-
Hispanic black and Hispanic populations again had a significantly lower prevalence of 
trisomy 21 compared with the non-Hispanic white population in the same age groups.
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Effect of Maternal Age Distribution, Prenatal Cytogenetic Testing, and Elective Termination 
on Prevalence of Trisomy 21
Some of these findings are in contrast to previous reports in the literature. Similar to our 
observations, some studies have reported a lower prevalence of trisomy 21 among non-
Hispanic blacks compared with non-Hispanic whites [Bishop et al., 1997; Canfield et al., 
2006; Shin et al., 2009]. Unlike our data, however, others have reported as much as a 20% 
higher prevalence of trisomy 21 in Hispanic populations compared with non-Hispanic 
whites, while others have found no statistically significant difference between these race–
ethnicity groups [Centers for Disease Control and Prevention, 1994; Bishop et al., 1997; 
Hook et al., 1999; Canfield et al., 2006; Shin et al., 2009]. Bishop et al. [1997] did report a 
slightly lower prevalence of trisomy 21 among Hispanics compared with non-Hispanic 
whites, but only after adjusting for the probability of survival to birth if elective termination 
had not been chosen; the unadjusted live birth prevalence reported by these authors is 
similar to other literature reporting a higher prevalence of trisomy 21 among Hispanics 
[Bishop et al., 1997]. We hypothesize that the cause of the lower prevalence of trisomy 21 
among Hispanics in the MACDP surveillance area may be at least twofold, as described 
below.
Maternal Age Distribution
The Hispanic population in the MACDP area might be younger than those populations 
reported in other studies, since they did not provide mean maternal age data. During the 
1996–2005 time period, the mean age of all women with pregnancies ≥20 weeks gestation 
(regardless of birth defect status) in the five-county MACDP area was 30.1 years (standard 
deviation 5.7) for non-Hispanic white mothers and 25.7 (standard deviation 5.7) for 
Hispanic mothers. There also was a greater proportion of mothers aged ≥35 years in the non-
Hispanic white population than in the Hispanic population (22.2% of non-Hispanic white 
mothers compared with 7.9% of Hispanic mothers). While not reaching the level of 
significance, the live birth prevalence of trisomy 21 for Hispanic mothers aged ≥35 years 
was higher than that for white mothers aged ≥35 (48.7 vs. 33.6 per 10,000 live births, 
respectively, Table I). The role of maternal age is supported by other data presented in Table 
I. The prevalence ratios for pregnancies affected by trisomy 21 in Hispanic women stratified 
by maternal age are 1.0 and 0.93 (<35 and ≥35, respectively), which are not significantly 
different from those for non-Hispanic white women. This comparison is most likely 
confounded by maternal age, as the overall PR is 0.64 for Hispanic women. If the maternal 
age distributions for these two race–ethnicity populations were more similar, the overall 
trisomy 21 live birth prevalence might shift towards a higher prevalence among Hispanics as 
has been reported by others.
Prenatal Cytogenetic Testing and Elective Termination
As seen in our data and noted by others [Baker et al., 2004; Jones et al., 2010; Pazol et al., 
2011], there is a significant difference in the prevalence of prenatal cytogenetic testing and 
of elective termination among race–ethnicity groups, which would affect the live birth 
prevalence [Mikkelsen, 1992; Cornel et al., 1993; Krivchenia et al., 1993; Bishop et al., 
1997; Forrester and Merz, 1999]. Although speculative, if the same frequencies of prenatal 
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cytogenetic testing and elective termination observed in the non-Hispanic white trisomy 21 
population were applied to the Hispanic trisomy 21 population, the live birth prevalence of 
trisomy 21 would be nearly identical for non-Hispanic whites and Hispanics (maternal age 
<35 years, 7.3 and 7.4 per 10,000 live births, respectively; maternal age ≥35 years, 33.9 and 
31.4 per 10,000 live births respectively). To our knowledge, no other study has analyzed the 
prevalence of trisomy 21 for these race–ethnicity groups in light of differences in the 
maternal age distribution, the frequency of prenatal testing, and the frequency of elective 
termination after a prenatal diagnosis, which may explain some of the disparate results seen 
in the literature and why our results differ from previous reports.
Limitations
There are several limitations to these analyses. These results represent the use of prenatal 
cytogenetic testing and elective termination within a population with confirmed birth 
defects, rather than within the general population of all pregnant women. Also, MACDP 
does not receive results from all cytogenetic laboratories that service Atlanta, which 
probably results in some under-ascertainment of the actual use of cytogenetic testing and of 
chromosomal diagnoses. Further, there may be differential ascertainment between race–
ethnicity groups as a result of the distribution of these groups within the catchment area, as 
well as differences in access to care. The limited number of cases particularly among the 
Hispanic population could influence the statistical stability of our estimates. Finally, the 
probability of survival to birth if elective termination had not been chosen might differ by 
race–ethnicity; the population used by Hook et al. [1989] to establish the 74% chance of 
survival was based on survey responses from prenatal cytogenetics laboratories in North 
America, however no demographic data or information about the responding laboratories 
were provided.
Strengths
This study has several strengths. This is a population-based study rather than hospital-based 
or a passive registry. Also, MACDP uses multiple ascertainment sources (such as birth 
hospitals, pediatric hospitals, specialty clinics, perinatal offices, cytogenetics laboratories, 
and vital records) to identify all infants, fetuses, or children with birth defects within the 
five-county catchment area. Highly trained MACDP abstractors actively search multiple 
sources at each ascertainment site and all medical records of identified cases are thoroughly 
reviewed to assure completeness of information. Finally, case abstractions are reviewed 
through a multi-tiered system involving pediatric and clinical genetics staff to ensure 
accuracy of diagnosis.
CONCLUSION
Overall, our data suggest that, in addition to possible biological causes such as maternal age, 
social factors (opinions about testing, attitudes regarding elective termination, and access to 
care) might play a large role in the race–ethnicity differences observed in the prevalence of 
trisomy 21.
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TABLE II
Adjusted Odds Ratios* for Prenatal Cytogenetic Testing and for Elective Termination Among Pregnancies 
With Birth Defects by Maternal Race–Ethnicity, Metropolitan Atlanta, 1996–2005
Non-Hispanic White Non-Hispanic Black Hispanic
All pregnancies with defects ascertained by MACDP 7,995 6,326 2,473
Prenatal cytogenetic test (PCT), n 1,550 912 208
  Odds ratio Referent 0.95 0.66a
  95% CI 0.87–1.0 0.56–0.78
Elective termination after PCT, n 325 130 29
  Odds ratio Referent 0.64* 0.66
  95% CI 0.51–0.81 0.43–1.0
Elective termination after abnormal PCT result, n 242 78 18
  Odds ratio Referent 0.50 0.49*
  95% CI 0.36–0.70 0.27–0.88
MACDP, Metropolitan Atlanta Congenital Defects Program; CI, confidence interval.
*
Adjusted for maternal age and year of index pregnancy.
a
Statistically significant difference compared to non-Hispanic white mothers.
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